scispace - formally typeset
Search or ask a question
Author

Rory Watson

Bio: Rory Watson is an academic researcher. The author has contributed to research in topics: European union & Legislation. The author has an hindex of 15, co-authored 248 publications receiving 1009 citations.


Papers
More filters
Journal ArticleDOI
26 Oct 2006-BMJ
TL;DR: The London based European Medicines Agency, after a month long investigation, has decided that the benefit-risk balance of non-selective non-steroidal antiinflammatory drugs (NSAIDs) remains favourable.
Abstract: The London based European Medicines Agency, after a month long investigation, has decided that the benefit-risk balance of non-selective non-steroidal antiinflammatory drugs (NSAIDs) remains favourable. The review, which was requested in September by France's national medicines agency, takes account of the publication of new data and analyses on thrombotic cardiovascular safety and develops initial recommendations made …

51 citations

Journal ArticleDOI
13 Sep 2007-BMJ
TL;DR: The first known instance of transmission of chikungunya fever by mosquitoes in Europe is currently taking place in northeastern Italy, where health authorities detected an unusually high number of cases of febrile illness.
Abstract: The first known instance of transmission of chikungunya fever by mosquitoes in Europe is currently taking place in northeastern Italy Previously some travellers from areas where the infection is endemic—parts of Africa, South East Asia, and the Indian subcontinent—had returned home to Europe with the virus But never before had local transmission taken place During August health authorities in the province of Emilia-Romagna detected an unusually high number of cases of febrile illness in two small villages near Ravenna, Castiglione di Cervia and Castiglione di Ravenna Subsequent analyses confirmed the diagnosis of chikungunya …

38 citations

Journal ArticleDOI
24 Mar 2009-BMJ
TL;DR: Luxembourg has become the third European country, after the Netherlands and Belgium, to legalise euthanasia in certain cases, and the law stipulates that doctors who carry out euthanasia and assisted suicides will not face “penal sanctions” or civil lawsuits.
Abstract: Luxembourg has become the third European country, after the Netherlands and Belgium, to legalise euthanasia in certain cases. The new legislation, which is accompanied by a parallel text on palliative care, will enter into force on 1 April. The law stipulates that doctors who carry out euthanasia and assisted suicides will not face “penal sanctions” or civil lawsuits as long as they first consult a colleague to ensure that the patient has a terminal illness, is in a “grave and incurable condition,” and has repeatedly asked for the right to die. Within eight days of helping a patient to …

27 citations

Journal ArticleDOI
27 Jan 2009-BMJ
TL;DR: The number of campylobacter infections in humans continues to rise across Europe, while the number of cases of salmonella is maintaining a downward trend, new data released in Brussels on 20 January show.
Abstract: The number of campylobacter infections in humans continues to rise across Europe, while the number of cases of salmonella is maintaining a downward trend, new data released in Brussels on 20 January show. The report on zoonoses, jointly produced by the European Food Safety Authority in Parma, Italy, and the European Centre for Disease Prevention and Control in Stockholm, provides the latest picture on the extent to which infectious diseases are transmitted from animals to humans in 31 European countries. Twenty two of the 27 European Union countries reported a rise in the number of confirmed cases …

23 citations

Journal ArticleDOI
19 Jun 2003-BMJ
TL;DR: European Union legislation due to take effect next year could seriously reduce the scope for non-commercial clinical trials, says Cancer Research UK.
Abstract: European Union legislation due to take effect next year could seriously reduce the scope for non-commercial clinical trials, says Cancer Research UK. The new rules are designed to simplify and harmonise the many different national provisions now in force relating to good practice in the conduct of clinical trials of medicinal products. Their aim is to ensure good care of patients and to make it easier to conduct pan-European research. But, as governments now prepare the enabling legislation to implement the EU rules in domestic …

22 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: Depressive symptoms and clinical depression have an unfavorable impact on mortality in CHD patients and depression has to be considered a relevant risk factor in patients with CHD.
Abstract: Background Prospective studies on physically healthy subjects have shown an association between depression and the subsequent development of coronary heart disease (CHD). The relative risk in meta-analytic aggregation is 1.64 (confidence interval [CI], 1.29-2.08) for any CHD event. However, the adverse impact of depression on CHD patients has not yet been the subject of a meta-analysis. Objective To quantify the impact of depressive symptoms (eg, BDI, HADS) or depressive disorders (major depression) on cardiac or all-cause mortality. We analyzed the strength of the relationship, the time dependency, and the differences in studies using depressive symptoms or a clinical diagnosis as predictors of mortality. Method English and German language databases (Medline, PsycInfo, PSYNDEX) from 1980 to 2003 were searched for prospective cohort studies. Sixty-two publications were identified. The inclusion criteria were met by 29 publications reporting on 20 studies. A random model was used to estimate the combined overall effect as crude odds ratios (OR) or adjusted hazard ratios (HR [adj]). Results Depressive symptoms increase the risk of mortality in CHD patients. The risk of depressed patients dying in the 2 years after the initial assessment is two times higher than that of nondepressed patients (OR, 2.24; 1.37-3.60). This negative prognostic effect also remains in the long-term (OR, 1.78; 1.12-2.83) and after adjustment for other risk factors (HR [adj], 1.76; 1.27-2.43). The unfavorable impact of depressive disorders was reported for the most part in the form of crude odds ratios. Within the first 6 months, depressive disorders were found to have no significant effect on mortality (OR, 2.07; CI, 0.82-5.26). However, after 2 years, the risk is more than two times higher for CHD patients with clinical depression (OR, 2.61; 1.53-4.47). Only three studies reported adjusted hazard ratios for clinical depression and supported the results of the bivariate models. Conclusions Depressive symptoms and clinical depression have an unfavorable impact on mortality in CHD patients. The results are limited by heterogeneity of the results in the primary studies. There is no clear evidence whether self-report or clinical interview is the more precise predictor. Nevertheless, depression has to be considered a relevant risk factor in patients with CHD.

1,296 citations

Journal ArticleDOI
TL;DR: This poster aims to demonstrate the efforts towards in-situ applicability of EMMARM, which aims to provide real-time information about the physical and cognitive properties of Alzheimer's disease and other dementias.
Abstract: Defeating Alzheimer's disease and other dementias : a priority for European science and society

1,215 citations

Journal ArticleDOI
TL;DR: These guidelines are intended to provide an overview of current knowledge on the subject with an assessment of the quality of the evidence in order to allow anaesthetists throughout Europe to integrate this knowledge into daily patient care wherever possible.
Abstract: The aims of severe perioperative bleeding management are three-fold. First, preoperative identification by anamesis and laboratory testing of those patients for whom the perioperative bleeding risk may be increased. Second, implementation of strategies for correcting preoperative anaemia and stabilisation of the macro- and microcirculations in order to optimise the patient’s tolerance to bleeding. Third, targeted procoagulant interventions to reduce the amount of bleeding, morbidity, mortality and costs. The purpose of these guidelines is to provide an overview of current knowledge on the subject with an assessment of the quality of the evidence in order to allow anaesthetists throughout Europe to integrate this knowledge into daily patient care wherever possible. The Guidelines Committee of the European Society of Anaesthesiology (ESA) formed a task force with members of scientific subcommittees and individual expert members of the ESA. Electronic databases were searched without language restrictions from the year 2000 until 2012. These searches produced 20 664 abstracts. Relevant systematic reviews with meta-analyses, randomised controlled trials, cohort studies, case-control studies and cross-sectional surveys were selected. At the suggestion of the ESA Guideline Committee, the Scottish Intercollegiate Guidelines Network (SIGN) grading system was initially used to assess the level of evidence and to grade recommendations. During the process of guideline development, the official position of the ESA changed to favour the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. This report includes general recommendations as well as specific recommendations in various fields of surgical interventions. The final draft guideline was posted on the ESA website for four weeks and the link was sent to all ESA members. Comments were collated and the guidelines amended as appropriate. When the final draft was complete, the Guidelines Committee and ESA Board ratified the guidelines.

883 citations

Journal ArticleDOI
TL;DR: The widespread use of the term eHealth suggests that it is an important concept, and that there is a tacit understanding of its meaning, according to a systematic review of published, suggested, or proposed definitions.
Abstract: CONTEXT: The term eHealth is widely used by many individuals, academic institutions, professional bodies, and funding organizations. It has become an accepted neologism despite the lack of an agreed-upon clear or precise definition. We believe that communication among the many individuals and organizations that use the term could be improved by comprehensive data about the range of meanings encompassed by the term. OBJECTIVE: To report the results of a systematic review of published, suggested, or proposed definitions of eHealth. DATA SOURCES: Using the search query string “eHealth” OR “e-Health” OR “electronic health”, we searched the following databases: Medline and Premedline (1966-June 2004), EMBASE (1980-May 2004), International Pharmaceutical Abstracts (1970-May 2004), Web of Science (all years), Information Sciences Abstracts (1966-May 2004), Library Information Sciences Abstracts (1969-May 2004), and Wilson Business Abstracts (1982-March 2004). In addition, we searched dictionaries and an Internet search engine. STUDY SELECTION: We included any source published in either print format or on the Internet, available in English, and containing text that defines or attempts to define eHealth in explicit terms. Two of us independently reviewed titles and abstracts of citations identified in the bibliographic databases and Internet search, reaching consensus on relevance by discussion. DATA EXTRACTION: We retrieved relevant reports, articles, references, letters, and websites containing definitions of eHealth. Two of us qualitatively analyzed the definitions and coded them for content, emerging themes, patterns, and novel ideas. DATA SYNTHESIS: The 51 unique definitions that we retrieved showed a wide range of themes, but no clear consensus about the meaning of the term eHealth. We identified 2 universal themes (health and technology) and 6 less general (commerce, activities, stakeholders, outcomes, place, and perspectives). CONCLUSIONS: The widespread use of the term eHealth suggests that it is an important concept, and that there is a tacit understanding of its meaning. This compendium of proposed definitions may improve communication among the many individuals and organizations that use the term. [J Med Internet Res 2005;7(1):e1]

854 citations

Journal ArticleDOI
TL;DR: Eco-effectiveness and cradle-to-cradle design as mentioned in this paper is an alternative design and production concept to the strategies of zero emission and ecoefficiency, where eco-efficiency and zero emission seek to reduce the unintended negative consequences of processes of production and consumption, while ecoeffectiveness is a positive agenda for the conception and production of goods and services that incorporate social, economic, and environmental benefit.

831 citations